

8 April 2025

## Annual General Meeting Date

Singapore-founded regenerative medicine company **Osteopore Limited (ASX:OSX or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting will be held on Friday, 30 May 2025.

An item of business at the AGM will be the re-election and appointment of directors. In accordance with clause 7.5 of the Company's Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Friday, 18 April 2025.

Any nominations must be received at the Company's registered office no later than 5:00pm (WST) on Friday, 18 April 2025.

### ENDS

*This announcement has been authorised for release to the ASX by the Company Secretary of Osteopore Limited.*

For more information, please contact:

**Dr Yujing Lim**

Chief Executive Officer

Osteopore Limited

E: [lim\\_yujing@osteopore.com](mailto:lim_yujing@osteopore.com)**Isaac Stewart**

Media &amp; Investor Relations

Purple

E: [istewart@purple.au](mailto:istewart@purple.au)

### About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.



## ASX ANNOUNCEMENT

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

### About Total Orthopaedics

Total Orthopaedic Care & Surgery is an orthopaedic specialist clinic in Singapore dedicated to providing comprehensive, evidence-based orthopaedic and musculoskeletal care to patients, with a focus on patient care, minimally invasive techniques, quality and accessibility.

### Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement.

This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

